New drug combo aims to tame transplant complications in blood cancer patients

NCT ID NCT04022239

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests the safety and best dose of bendamustine, given with or without cyclophosphamide, to prevent graft-versus-host disease (GVHD) in 25 blood cancer patients receiving a stem cell transplant. GVHD occurs when donor cells attack the patient's body. The approach combines chemotherapy and radiation before transplant with immune-suppressing drugs after transplant to reduce this risk. The goal is to find a dose that controls GVHD without causing too many side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM